BioWorld MedTech

Nov. 18, 2016

View Archived Issues

Disappointed Endologix stumbles as FDA calls for more Nellix EVAS system data

A "disappointed" Endologix Inc. (Nasdaq:ELGX) now is anticipating a second quarter 2018 approval of the Nellix endovascular aneurysm sealing (EVAS) system following the FDA's request for two-year patient follow-up data. Read More

FDA relaxes imaging protocol mandates in 510(k) final for MR

Read More

China med tech a hot sector for M&A thanks to regulatory reforms

Read More

Limflow wins CE mark for device sparing lower limbs for No-Option patients

Read More

What's next now that the JOBS Act is fully implemented?

Read More

Financings

Read More

Product briefs

Read More

Appointments and advancements

Read More

MDD's Diagnostics Extra

Read More